Author
Andreas L. Birkenfeld
Other affiliations: Max Delbrück Center for Molecular Medicine, University of Cambridge, Ludwig Maximilian University of Munich ...read more
Bio: Andreas L. Birkenfeld is an academic researcher from King's College London. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 36, co-authored 113 publications receiving 6362 citations. Previous affiliations of Andreas L. Birkenfeld include Max Delbrück Center for Molecular Medicine & University of Cambridge.
Papers published on a yearly basis
Papers
More filters
••
Adrian F. Hernandez1, Jennifer B. Green1, Salim Janmohamed2, Ralph B. D'Agostino3 +795 more•Institutions (7)
TL;DR: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events, and evidence-based glucagon-like peptide 1 receptor agonists should be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events.
1,064 citations
••
King's College London1, University of Cambridge2, University of Leicester3, Catholic University of the Sacred Heart4, HealthPartners5, Nanyang Technological University6, Tan Tock Seng Hospital7, University of Southampton8, University of Miami9, University of Amsterdam10, Centre national de la recherche scientifique11, Anschutz Medical Campus12, Monash University13, Imperial College London14, State University of Campinas15, The Chinese University of Hong Kong16, Peking University17
TL;DR: An international panel of experts in the field of diabetes and endocrinology is formed to provide some guidance and practical recommendations for the management of diabetes during the COVID-19 pandemic.
659 citations
••
TL;DR: This review will discuss recent studies in both humans and animal models of NAFLD that have implicated increases in hepatic diacylglycerol content leading to activation of novel protein kinase Cϵ (PKCϵ) resulting in decreased insulin signaling in the pathogenesis ofNAFLD‐associated hepatic insulin resistance and type 2 diabetes.
584 citations
••
TL;DR: Preliminary data suggest that people with obesity are at increased risk of severe COVID-19, but as data on metabolic parameters in patients with CO VID-19 are scarce, increased reporting is needed to improve understanding of the drug and the care of affected patients.
Abstract: Preliminary data suggest that people with obesity are at increased risk of severe COVID-19. However, as data on metabolic parameters (such as BMI and levels of glucose and insulin) in patients with COVID-19 are scarce, increased reporting is needed to improve our understanding of COVID-19 and the care of affected patients.
456 citations
••
TL;DR: In combination with dietary and physical activity counselling, semaglutide was well tolerated over 52 weeks and showed clinically relevant weight loss compared with placebo at all doses.
378 citations
Cited by
More filters
••
TL;DR: This guidance provides a data-supported approach to the diagnostic, therapeutic, and preventive aspects of NAFLD care.
4,431 citations
••
Turku University Hospital1, National University of Ireland, Galway2, University of Catania3, University of Naples Federico II4, University of Paris5, Bispebjerg Hospital6, University of Sheffield7, University of Cambridge8, Stavanger University Hospital9, Oslo University Hospital10, Hospital Clínico San Carlos11, Mayo Clinic12, University of Western Brittany13, Rabin Medical Center14, Slovak Medical University15, Saarland University16, University of Barcelona17, University of Brescia18, University of Bern19, University of Erlangen-Nuremberg20, Leiden University Medical Center21
TL;DR: In this article, the authors present guidelines for the management of patients with coronary artery disease (CAD), which is a pathological process characterized by atherosclerotic plaque accumulation in the epicardial arteries.
Abstract: Coronary artery disease (CAD) is a pathological process characterized by atherosclerotic plaque accumulation in the epicardial arteries, whether obstructive or non-obstructive. This process can be modified by lifestyle adjustments, pharmacological therapies, and invasive interventions designed to achieve disease stabilization or regression. The disease can have long, stable periods but can also become unstable at any time, typically due to an acute atherothrombotic event caused by plaque rupture or erosion. However, the disease is chronic, most often progressive, and hence serious, even in clinically apparently silent periods. The dynamic nature of the CAD process results in various clinical presentations, which can be conveniently categorized as either acute coronary syndromes (ACS) or chronic coronary syndromes (CCS). The Guidelines presented here refer to the management of patients with CCS. The natural history of CCS is illustrated in Figure 1.
3,448 citations
••
TL;DR: Patrick T. O’Gara, MD, MACC, FAHA, Chair Joshua A. Beckman,MD, MS, FAha, Chair-Elect Glenn N. Levine, MD., Immediate Past Chair Sana M. Al-Khatib, MD.
2,572 citations
••
TL;DR: A correction has been published: European Heart Journal, ehaa895, https://doi.org/10.1093/eurheartj/ehaa-895.
Abstract: A correction has been published: European Heart Journal, ehaa895, https://doi.org/10.1093/eurheartj/ehaa895
2,361 citations
••
TL;DR: This work has shown that changes in fatty acid uptake, lipogenesis, and energy expenditure that can impact ectopic lipid deposition may converge to promote the accumulation of specific lipid metabolites in liver and skeletal muscle, a common final pathway leading to impaired insulin signaling and insulin resistance.
1,831 citations